Immunomodulatory therapies for cystic fibrosis

Austin Bassett Thompson, William L. Smits, Robert B. Fick

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Progressive pulmonary disease is the primary cause of morbidity and mortality in adult patients with cystic fibrosis (CF). The decrease in lung function associated with infection with Pseudomonas aeruginosa has been related to the severity of pulmonary inflammation. Thus therapies that reduce pulmonary inflammation may prove to be clinically efficacious. Therapeutic interventions that target pulmonary inflammation may be directed either at the infecting organism, especially P aeruginosa, or at host responses. Eradication of P aeruginosa from the airways of patients with CF has not been accomplished. However, reduction of the burden of P aeruginosa or modification of virulence factors are practical goals. Normalization of the host response ultimately depends on correction of the molecular defect. Until then, therapies are bein investigated that may modulate pulmonary inflammation. These include therapies aimed at compensating for the defect in ion transport, down-regulating inflammatory cell responses, inhibiting host inflammatory products, or altering airway secretions. Preliminary data suggest that each of these approaches may have clinical efficacy. Large, multicenter trials addressing these issues are presently ongoing and hold the promise for continued improvement in the clinical course of patients with CF.

Original languageEnglish (US)
Pages (from-to)218-226
Number of pages9
JournalSeminars in Respiratory Infections
Volume7
Issue number3
StatePublished - Sep 1 1992

Fingerprint

Immunomodulation
Cystic Fibrosis
Pneumonia
Ion Transport
Virulence Factors
Therapeutics
Pseudomonas aeruginosa
Lung Diseases
Multicenter Studies
Morbidity
Lung
Mortality
Infection

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Microbiology (medical)

Cite this

Immunomodulatory therapies for cystic fibrosis. / Thompson, Austin Bassett; Smits, William L.; Fick, Robert B.

In: Seminars in Respiratory Infections, Vol. 7, No. 3, 01.09.1992, p. 218-226.

Research output: Contribution to journalArticle

Thompson, AB, Smits, WL & Fick, RB 1992, 'Immunomodulatory therapies for cystic fibrosis', Seminars in Respiratory Infections, vol. 7, no. 3, pp. 218-226.
Thompson, Austin Bassett ; Smits, William L. ; Fick, Robert B. / Immunomodulatory therapies for cystic fibrosis. In: Seminars in Respiratory Infections. 1992 ; Vol. 7, No. 3. pp. 218-226.
@article{4dd8014be4ea4368a2fa57b8fe0d5507,
title = "Immunomodulatory therapies for cystic fibrosis",
abstract = "Progressive pulmonary disease is the primary cause of morbidity and mortality in adult patients with cystic fibrosis (CF). The decrease in lung function associated with infection with Pseudomonas aeruginosa has been related to the severity of pulmonary inflammation. Thus therapies that reduce pulmonary inflammation may prove to be clinically efficacious. Therapeutic interventions that target pulmonary inflammation may be directed either at the infecting organism, especially P aeruginosa, or at host responses. Eradication of P aeruginosa from the airways of patients with CF has not been accomplished. However, reduction of the burden of P aeruginosa or modification of virulence factors are practical goals. Normalization of the host response ultimately depends on correction of the molecular defect. Until then, therapies are bein investigated that may modulate pulmonary inflammation. These include therapies aimed at compensating for the defect in ion transport, down-regulating inflammatory cell responses, inhibiting host inflammatory products, or altering airway secretions. Preliminary data suggest that each of these approaches may have clinical efficacy. Large, multicenter trials addressing these issues are presently ongoing and hold the promise for continued improvement in the clinical course of patients with CF.",
author = "Thompson, {Austin Bassett} and Smits, {William L.} and Fick, {Robert B.}",
year = "1992",
month = "9",
day = "1",
language = "English (US)",
volume = "7",
pages = "218--226",
journal = "Seminars in Respiratory Infections",
issn = "0882-0546",
publisher = "W.B. Saunders Ltd",
number = "3",

}

TY - JOUR

T1 - Immunomodulatory therapies for cystic fibrosis

AU - Thompson, Austin Bassett

AU - Smits, William L.

AU - Fick, Robert B.

PY - 1992/9/1

Y1 - 1992/9/1

N2 - Progressive pulmonary disease is the primary cause of morbidity and mortality in adult patients with cystic fibrosis (CF). The decrease in lung function associated with infection with Pseudomonas aeruginosa has been related to the severity of pulmonary inflammation. Thus therapies that reduce pulmonary inflammation may prove to be clinically efficacious. Therapeutic interventions that target pulmonary inflammation may be directed either at the infecting organism, especially P aeruginosa, or at host responses. Eradication of P aeruginosa from the airways of patients with CF has not been accomplished. However, reduction of the burden of P aeruginosa or modification of virulence factors are practical goals. Normalization of the host response ultimately depends on correction of the molecular defect. Until then, therapies are bein investigated that may modulate pulmonary inflammation. These include therapies aimed at compensating for the defect in ion transport, down-regulating inflammatory cell responses, inhibiting host inflammatory products, or altering airway secretions. Preliminary data suggest that each of these approaches may have clinical efficacy. Large, multicenter trials addressing these issues are presently ongoing and hold the promise for continued improvement in the clinical course of patients with CF.

AB - Progressive pulmonary disease is the primary cause of morbidity and mortality in adult patients with cystic fibrosis (CF). The decrease in lung function associated with infection with Pseudomonas aeruginosa has been related to the severity of pulmonary inflammation. Thus therapies that reduce pulmonary inflammation may prove to be clinically efficacious. Therapeutic interventions that target pulmonary inflammation may be directed either at the infecting organism, especially P aeruginosa, or at host responses. Eradication of P aeruginosa from the airways of patients with CF has not been accomplished. However, reduction of the burden of P aeruginosa or modification of virulence factors are practical goals. Normalization of the host response ultimately depends on correction of the molecular defect. Until then, therapies are bein investigated that may modulate pulmonary inflammation. These include therapies aimed at compensating for the defect in ion transport, down-regulating inflammatory cell responses, inhibiting host inflammatory products, or altering airway secretions. Preliminary data suggest that each of these approaches may have clinical efficacy. Large, multicenter trials addressing these issues are presently ongoing and hold the promise for continued improvement in the clinical course of patients with CF.

UR - http://www.scopus.com/inward/record.url?scp=0027102006&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027102006&partnerID=8YFLogxK

M3 - Article

VL - 7

SP - 218

EP - 226

JO - Seminars in Respiratory Infections

JF - Seminars in Respiratory Infections

SN - 0882-0546

IS - 3

ER -